Business Context and Reporting Period
This Form 8-K filing by IDEAYA Biosciences, Inc. (IDYA) reports a material event occurring on September 23, 2020, with the report filed on September 24, 2020. The Company is a Delaware corporation focused on developing targeted therapies for solid tumors.
Key Financial Metrics
This filing is a Current Report regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change is the entry into an amendment of the Clinical Trial Collaboration and Supply Agreement with Pfizer Inc., originally dated March 11, 2020. Key changes include:
- Expansion of collaboration to include a new Phase 1/2 study (IDE196/Crizotinib Combination Study) for Metastatic Uveal Melanoma and other solid tumors with GNAQ or GNA11 mutations.
- IDEAYA will sponsor the new study, provide the IDE196 compound, and bear the costs.
- Pfizer will provide crizotinib at no cost to IDEAYA.
- Clinical data and inventions from the new combination study will be jointly owned.
- A joint development committee will coordinate regulatory activities for both the new study and the existing IDE196/Binimetinib Combination Study.
Guidance, Outlook, and Risks
Management indicated that if clinical data from either combination study is positive, the parties will enter into good faith negotiations to determine a regulatory submission strategy. The filing notes that the summary is qualified by the full Amendment, which will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2020. No specific financial guidance or risk factors beyond the standard reliance on the full agreement text are detailed in this specific 8-K.
Investor Verification Checklist
- Verify the full terms of the Amendment in the upcoming Form 10-Q exhibit.
- Monitor the initiation and enrollment status of the IDE196/Crizotinib Combination Study.
- Assess the impact of IDEAYA bearing the full cost of the new study on future cash burn rates.
- Track the formation and activities of the joint development committee with Pfizer.